CV Advisors’s C4 Therapeutics CCCC Stock Holding History

CV Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$216K	Hold	65,000	–	–	0.04%	108
2026 Q2	$304K	Buy	+65,000	New	+$222K	0.06%	106

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

CV Advisors's CCCC Position: Q3 2026 in Review

CV Advisors held its C4 Therapeutics (CCCC) position steady in Q3 2026 at 65,000 shares worth $216K. The position accounts for 0.04% of the portfolio, ranked #108.

CV Advisors first reported a position in CCCC in Q2 2026 and has held it in 2 quarters since. The position peaked at $304K in Q2 2026. 8 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

CV Advisors held 65,000 shares of C4 Therapeutics worth $216K as of Q3 2026.
CV Advisors left its C4 Therapeutics share count unchanged in Q3 2026.
C4 Therapeutics made up 0.04% of CV Advisors's portfolio in Q3 2026, its #108 holding.
CV Advisors first reported a position in C4 Therapeutics in Q2 2026 and has held it in 2 quarters since.
CV Advisors's C4 Therapeutics position peaked at $304K in Q2 2026.
8 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on CV Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.